Europe could recommend second biosimilar arthritis drug this week

By Ben Hirschler LONDON (Reuters) – Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis’s copy of Enbrel. Biosimilar copies of expensive biotech drugs are gaining momentum in Europe, which has been faster to adopt their use than the United States, and antibodies are the big prize because these products are among the world’s top-selling drugs. Worldwide sales of Amgen’s Enbrel, which is marketed outside North America by Pfizer, totalled $9 billion last year, with Europe accounting for about $2.5 billion.
Go to Source

WHO warns of widespread misunderstanding of superbug threat

By Kate Kelland LONDON (Reuters) – People across the world are confused about the major threat to public health posed by drug-resistant superbugs and do not know how to stop that risk growing, the World Health Organization (WHO) said on Monday. Ramping up its fight against antibiotic resistance with a survey of public awareness, the United Nations health agency said 64 percent of those asked believed wrongly that penicillin-based drugs and other antibiotics can treat colds and flu, despite the fact such medicines have no impact on viruses. Around a third of people surveyed also wrongly believed they should stop taking antibiotics when they feel better, rather than completing the prescribed treatment course, the WHO said.
Go to Source

1 3 4 5 6 7 10